FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311014353> ?p ?o ?g. }

• W4311014353 endingPage "7094" @default.
• W4311014353 startingPage "7094" @default.
• W4311014353 abstract "Background: There are multiple glucose-lowering drugs available as alternative initial monotherapy for type 2 diabetes patients with contraindications or intolerance to metformin. However, little comparative and systematic data are available for them as initial monotherapy. This study estimated and compared the treatment effects of glucose-lowering drugs as initial monotherapy for type 2 diabetes. Methods: PubMed, Web of Science, Embase, CNKI, Chongqing VIP, and WanFang Data from 1 January 1990 until 31 December 2020 were searched for randomized controlled trials which compared a glucose-lowering drug with placebo/lifestyle-intervention for type 2 diabetes. Drug classes included metformin, sulfonylureas (SUs), thiazolidinediones (TZDs), glinides (NIDEs), α-glucosidase inhibitors (AGIs), dipeptidyl peptidase-4 inhibitors (DPP-4is), sodium-glucose cotransporter-2 inhibitors (SGLT2is), insulins (INSs), and glucagon-like peptide-1 receptor agonists (GLP-1RAs). Results: A total of 185 trials were included, identifying 38,376 patients from 56 countries across six continents. When choosing an initial drug monotherapy alternative to metformin, SUs were most efficacious in reducing HbA1c (−1.39%; 95% CI −1.63, −1.16) and FPG (−2.70 mmol/L; 95% CI −3.18, −2.23), but increased hypoglycemia risks (5.44; 95% CI 2.11, 14.02). GLP-1RAs were most efficacious in reducing BMI (−1.05 kg/m2; 95% CI −1.81, −0.29) and TC (−0.42 mmol/L; 95% CI −0.61, −0.22). TZDs were most efficacious in increasing HDL-C (0.12 mmol/L; 95% CI 0.07, 0.17). SGLT2is were most efficacious in lowering SBP (−4.18 mmHg; 95% CI −4.84, −3.53). While AGIs conferred higher risk of AE-induced discontinuations (2.57; 95% CI 1.64, 4.03). Overall, only GLP-1RAs showed an integrated beneficial effect on all outcomes. Our results also confirmed the intraclass differences in treatment effects across drugs. Most trials were short-term, and no significant differences in mortality, total vascular events, myocardial infarction, heart failure, stroke, or diabetic nephropathy were observed across drug classes. Conclusions: Our results suggest a potential treatment hierarchy for decision-makers, with GLP-1RAs being the preferred alternative therapy to metformin regarding their favorable efficacy and safety profiles." @default.
• W4311014353 created "2022-12-22" @default.
• W4311014353 creator A5007249812 @default.
• W4311014353 creator A5009673182 @default.
• W4311014353 creator A5023374201 @default.
• W4311014353 creator A5040128172 @default.
• W4311014353 creator A5062294085 @default.
• W4311014353 creator A5069523303 @default.
• W4311014353 creator A5079075083 @default.
• W4311014353 creator A5080297407 @default.
• W4311014353 date "2022-11-30" @default.
• W4311014353 modified "2023-09-30" @default.
• W4311014353 title "Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis" @default.
• W4311014353 cites W1544352279 @default.
• W4311014353 cites W1556459089 @default.
• W4311014353 cites W1585447752 @default.
• W4311014353 cites W1604542334 @default.
• W4311014353 cites W1605983684 @default.
• W4311014353 cites W1771498646 @default.
• W4311014353 cites W1906367066 @default.
• W4311014353 cites W1921132582 @default.
• W4311014353 cites W192146159 @default.
• W4311014353 cites W1964438054 @default.
• W4311014353 cites W1966243777 @default.
• W4311014353 cites W1968552143 @default.
• W4311014353 cites W1968736342 @default.
• W4311014353 cites W1969081771 @default.
• W4311014353 cites W1970125713 @default.
• W4311014353 cites W1971471384 @default.
• W4311014353 cites W1973383046 @default.
• W4311014353 cites W1979078348 @default.
• W4311014353 cites W1979721671 @default.
• W4311014353 cites W1981183973 @default.
• W4311014353 cites W1987234886 @default.
• W4311014353 cites W1992335598 @default.
• W4311014353 cites W1995232262 @default.
• W4311014353 cites W1999892123 @default.
• W4311014353 cites W2001991301 @default.
• W4311014353 cites W2003323316 @default.
• W4311014353 cites W2003606333 @default.
• W4311014353 cites W2005379446 @default.
• W4311014353 cites W2005947177 @default.
• W4311014353 cites W2012117258 @default.
• W4311014353 cites W2012211007 @default.
• W4311014353 cites W2013991546 @default.
• W4311014353 cites W2014397018 @default.
• W4311014353 cites W2015191704 @default.
• W4311014353 cites W2015279471 @default.
• W4311014353 cites W2017266270 @default.
• W4311014353 cites W2020827332 @default.
• W4311014353 cites W2020831729 @default.
• W4311014353 cites W2020984463 @default.
• W4311014353 cites W2022707538 @default.
• W4311014353 cites W2023329893 @default.
• W4311014353 cites W2023432450 @default.
• W4311014353 cites W2033417941 @default.
• W4311014353 cites W2041113527 @default.
• W4311014353 cites W2041987319 @default.
• W4311014353 cites W2042200044 @default.
• W4311014353 cites W2043092889 @default.
• W4311014353 cites W2047199620 @default.
• W4311014353 cites W2047353065 @default.
• W4311014353 cites W2049323977 @default.
• W4311014353 cites W2050722926 @default.
• W4311014353 cites W2051462052 @default.
• W4311014353 cites W2054841007 @default.
• W4311014353 cites W2056645339 @default.
• W4311014353 cites W2056710240 @default.
• W4311014353 cites W2056726092 @default.
• W4311014353 cites W2059623316 @default.
• W4311014353 cites W2060356225 @default.
• W4311014353 cites W2061936289 @default.
• W4311014353 cites W2063566303 @default.
• W4311014353 cites W2063976195 @default.
• W4311014353 cites W2064635494 @default.
• W4311014353 cites W2066614694 @default.
• W4311014353 cites W2067448646 @default.
• W4311014353 cites W2067579363 @default.
• W4311014353 cites W2068171948 @default.
• W4311014353 cites W2069942402 @default.
• W4311014353 cites W2072866190 @default.
• W4311014353 cites W2079769148 @default.
• W4311014353 cites W2079850075 @default.
• W4311014353 cites W2081936370 @default.
• W4311014353 cites W2083808413 @default.
• W4311014353 cites W2084744936 @default.
• W4311014353 cites W2085489793 @default.
• W4311014353 cites W2085862152 @default.
• W4311014353 cites W2087539094 @default.
• W4311014353 cites W2087748897 @default.
• W4311014353 cites W2091422449 @default.
• W4311014353 cites W2092252523 @default.
• W4311014353 cites W2095948962 @default.
• W4311014353 cites W2096048424 @default.
• W4311014353 cites W2100064046 @default.
• W4311014353 cites W2100238245 @default.
• W4311014353 cites W2101293928 @default.
• W4311014353 cites W2102382908 @default.

• next